Noncoding RNA in drug resistant sarcoma

Xiaoyang Li; Jacson K. Shen; Francis J. Hornicek; Tao Xiao; Zhenfeng Duan

doi:10.18632/oncotarget.19029

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Noncoding RNA in drug resistant sarcoma

Xiaoyang Li, Jacson K. Shen, Francis J. Hornicek, Tao Xiao _ and Zhenfeng Duan

PDF | HTML | How to cite

Oncotarget. 2017; 8:69086-69104. https://doi.org/10.18632/oncotarget.19029

Metrics: PDF 1539 views | HTML 3982 views | ?

Abstract

Xiaoyang Li1,2, Jacson K. Shen2, Francis J. Hornicek2, Tao Xiao1 and Zhenfeng Duan2

1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China

2Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114, USA

Correspondence to:

Tao Xiao, email: [email protected]

Zhenfeng Duan, email: [email protected]

Keywords: noncoding RNA (ncRNA), microRNA (miR), long noncoding RNA (lncRNA), drug resistance, sarcoma

Received: May 04, 2017 Accepted: June 26, 2017 Published: July 06, 2017

ABSTRACT

Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant development of multidisciplinary treatments for sarcoma, survival rates have reached a plateau. Chemotherapy has been extensively used for sarcoma treatment; however, the development of drug resistance is a major obstacle limiting the success of many anticancer agents. Sarcoma biology has traditionally focused on genomic and epigenomic deregulation of protein-coding genes to identify the therapeutic potential for reversing drug resistance. New and more creative approaches have found the involvement of noncoding RNAs, including microRNAs and long noncoding RNAs in drug resistant sarcoma. In this review, we discuss the current knowledge of noncoding RNAs characteristics and the regulated genes involved in drug resistant sarcoma, and focus on their therapeutic potential in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19029

Publication Alerts

Reviews:

Noncoding RNA in drug resistant sarcoma

Abstract